Published in Semin Oncol on August 01, 2004
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol (2009) 1.61
Angiogenesis in cancer. Vasc Health Risk Manag (2006) 1.49
Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs. J Exp Clin Cancer Res (2009) 0.90
The effect of neoadjuvant chemoradiotherapy on airway colonization and postoperative respiratory complications in patients undergoing oesophagectomy for oesophageal cancer. Interact Cardiovasc Thorac Surg (2012) 0.81
Treatment strategies for oesophageal cancer - time-trends and long term outcome data from a large tertiary referral centre. Radiat Oncol (2012) 0.77
A randomized study to compare sequential chemoradiotherapy with concurrent chemoradiotherapy for unresectable locally advanced esophageal cancer. Indian J Med Paediatr Oncol (2014) 0.76
Accelerated or hyperfractionated radiotherapy for esophageal carcinoma: a meta-analysis of randomized controlled trials. Onco Targets Ther (2017) 0.75
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2005) 4.10
Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA (2005) 3.46
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol (2007) 3.19
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. Ann Surg Oncol (2003) 2.69
Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum (2004) 2.52
Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol (2013) 2.43
American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol (2007) 2.41
Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg (2009) 2.32
The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys (2005) 2.18
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol (2008) 2.07
Have the changes in treatment of rectal cancer made a significant difference to our patients? Oncology (Williston Park) (2011) 2.06
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol (2003) 2.04
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol (2008) 1.93
Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol (2005) 1.92
Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg (2002) 1.66
Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg (2002) 1.65
Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg (2005) 1.64
Residual mesorectal lymph node involvement following neoadjuvant combined-modality therapy: rationale for radical resection? Ann Surg Oncol (2004) 1.62
Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy. Int J Colorectal Dis (2003) 1.59
Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol (2004) 1.58
Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol (2009) 1.55
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol (2011) 1.54
Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. Ann Surg Oncol (2004) 1.54
Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer (2008) 1.53
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Ann Surg Oncol (2002) 1.50
T1 adenocarcinoma of the rectum: transanal excision or radical surgery? Ann Surg (2005) 1.49
Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. Ann Surg (2009) 1.48
Long-term results of local excision for rectal cancer. Ann Surg (2002) 1.44
Sphincter preservation for rectal cancer: fact or fiction? J Clin Oncol (2002) 1.39
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol (2010) 1.37
The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer. Dis Colon Rectum (2005) 1.37
Gastric cancer. J Natl Compr Canc Netw (2010) 1.35
Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg (2004) 1.32
A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol (2006) 1.26
NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw (2009) 1.24
Squamous-cell carcinoma of the rectum: a rare but curable tumor. Dis Colon Rectum (2007) 1.20
Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. Radiother Oncol (2009) 1.18
Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. J Clin Oncol (2005) 1.16
Patient acuity rating: quantifying clinical judgment regarding inpatient stability. J Hosp Med (2011) 1.15
Targeted therapies for esophageal cancer. Oncologist (2005) 1.11
Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol (2003) 1.07
Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. J Clin Oncol (2006) 1.07
Increased endocrine cells in treated rectal adenocarcinomas: a possible reflection of endocrine differentiation in tumor cells induced by chemotherapy and radiotherapy. Am J Surg Pathol (2002) 1.06
Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol (2013) 1.06
Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum (2008) 1.06
The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. Int J Radiat Oncol Biol Phys (2003) 1.05
Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer (2011) 1.05
Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol (2004) 1.05
Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). J Clin Oncol (2009) 1.04
Colorectal cancer pelvic recurrences: determinants of resectability. Dis Colon Rectum (2004) 1.02
A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation. Ann Surg (2007) 1.02
Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy. Am J Surg Pathol (2011) 1.01
Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol (2007) 1.01
Radiation therapy facilities in the United States. Int J Radiat Oncol Biol Phys (2006) 1.01
Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum (2005) 1.01
Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. Dis Colon Rectum (2004) 1.00
Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw (2006) 1.00
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 0.99
Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys (2005) 0.99
Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis. Ann Surg Oncol (2011) 0.97
Esophagogastric cancer: targeted agents. Cancer Treat Rev (2010) 0.97
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs (2010) 0.95
Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy. J Clin Oncol (2008) 0.94
Sacral resection for recurrent rectal cancer: analysis of morbidity and treatment results. Dis Colon Rectum (2006) 0.94
Esophageal cancer. J Natl Compr Canc Netw (2008) 0.93
Predictors of survival in recurrent rectal cancer after resection and intraoperative radiotherapy. Dis Colon Rectum (2002) 0.93
Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service. J Am Coll Surg (2005) 0.93
A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg (2002) 0.92
The multidisciplinary rectal cancer treatment: main convergences, controversial aspects and investigational areas which support the need for an European Consensus. Radiother Oncol (2005) 0.92
Primary adenocarcinoma of the anus treated with combined modality therapy. Dis Colon Rectum (2003) 0.91
Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers. Ann Surg Oncol (2013) 0.90
Esophageal cancer: adjuvant therapy. Cancer J (2007) 0.89
Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection? J Clin Oncol (2005) 0.89
Adjuvant management of rectal cancer: the more we learn, the less we know. J Clin Oncol (2007) 0.89
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol (2008) 0.89
Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw (2006) 0.87
Management of gastric cancer. Curr Opin Gastroenterol (2014) 0.86
Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys (2010) 0.86
Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys (2004) 0.86
Targeted agents and esophageal cancer--the next step? Semin Radiat Oncol (2007) 0.85
Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan. J Clin Oncol (2007) 0.85
Can differences in bowel function after surgery for rectal cancer be identified by the European Organization for Research and Treatment of Cancer quality of life instrument? Ann Surg Oncol (2007) 0.84
Combined modality therapy in esophageal cancer: the Memorial experience. Semin Surg Oncol (2003) 0.84
Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. Ann Surg Oncol (2012) 0.84
Role of neoadjuvant therapy for esophageal adenocarcinoma. Surg Oncol Clin N Am (2009) 0.83
Evaluation of preoperative and postoperative radiotherapy on long-term functional results of straight coloanal anastomosis. Dis Colon Rectum (2003) 0.83
Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer. Gastrointest Cancer Res (2011) 0.82
Chemotherapeutic options for gastroesophageal junction tumors. Semin Radiat Oncol (2013) 0.82
Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus. J Clin Oncol (2005) 0.82
Emerging tyrosine kinase inhibitors for esophageal cancer. Expert Opin Emerg Drugs (2013) 0.82